967 related articles for article (PubMed ID: 17622750)
1. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats.
Weissgarten J; Berman S; Efrati S; Rapoport M; Averbukh Z; Feldman L
Nephrol Dial Transplant; 2006 May; 21(5):1198-204. PubMed ID: 16449288
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.
Tencer L; Burgermeister E; Ebert MP; Liscovitch M
Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034
[TBL] [Abstract][Full Text] [Related]
7. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA
Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846
[TBL] [Abstract][Full Text] [Related]
9. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
Xiao J; Leung JC; Chan LY; Guo H; Lai KN
Nephrol Dial Transplant; 2009 Jul; 24(7):2067-77. PubMed ID: 19155534
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
12. PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation.
Ren Y; Sun C; Sun Y; Tan H; Wu Y; Cui B; Wu Z
Vascul Pharmacol; 2009; 51(2-3):169-74. PubMed ID: 19540934
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
14. Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation.
Ulrich S; Wächtershäuser A; Loitsch S; von Knethen A; Brüne B; Stein J
Exp Cell Res; 2005 Oct; 310(1):196-204. PubMed ID: 16112107
[TBL] [Abstract][Full Text] [Related]
15. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells.
Cheng Y; Ping J; Xu LM
Chin Med J (Engl); 2007 May; 120(9):794-801. PubMed ID: 17531121
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
[TBL] [Abstract][Full Text] [Related]
17. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection.
Romera C; Hurtado O; Mallolas J; Pereira MP; Morales JR; Romera A; Serena J; Vivancos J; Nombela F; Lorenzo P; Lizasoain I; Moro MA
J Cereb Blood Flow Metab; 2007 Jul; 27(7):1327-38. PubMed ID: 17213861
[TBL] [Abstract][Full Text] [Related]
18. The peroxisome proliferator-activated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells.
Lovekamp-Swan T; Chaffin CL
Mol Cell Endocrinol; 2005 Apr; 233(1-2):15-24. PubMed ID: 15767042
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
